ASEP MEDICAL HOLDINGS INC - SEPSF STOCK NEWS

Asep Medical Holdings Inc. announces the formal registration of its joint venture company SepSMART with Sansure Biotech Inc. in China, completing the JV Agreement. Performance warrants have been issued to Sansure, exercisable into Asep common shares at $1.00 per share.

Asep Medical Holdings Inc. announces an online webinar to provide updates on its latest milestones, including diagnostic and therapeutic technologies.

Asep Medical Holdings Inc. presented groundbreaking AI technology for developing new biofilm infection treatments and a blood-based gene expression test for sepsis. AI methods predicted improved peptides with high biofilm activity, leading to potential new treatments. The SepsetER test, developed using AI, accurately predicts sepsis onset with just 6 genes. AI simplified the complexity of sepsis, identifying patient groupings with different immune defects. Asep aims to address antibiotic failure by developing antimicrobial peptides using AI, showing promising results.

Asep Medical Holdings Inc. announces a breakthrough in sepsis assessment for children with appendicitis through its gene expression signature, potentially revolutionizing diagnostic accuracy. The study published in JAMA Pediatrics showcases the effectiveness of Asep's AI-based sepsis diagnostic technology, SepsetER, in distinguishing between simple and perforated appendicitis.

Asep Medical Holdings Inc. (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) issues 3,915,930 units in settlement of debt, including an Insider Settlement with the Chief Financial Officer. Each unit consists of one common share and one common share purchase warrant, with the warrants exercisable into one common share at a price of $0.26 per warrant share until December 27, 2025.

Asep Medical Holdings Inc. (Asep Inc.) (ASEP) is pleased to announce the successful patent approval of its AI-based sepsis diagnostic technology, SepsetER TM, in the United States. The US patent, in addition to European and Australian patents, validates the Company's unique AI-based approach to sepsis diagnosis, a disease causing more than 11 million deaths annually. The test enables earlier and faster risk assessment of sepsis and targeted treatment, with plans for formal clinical 510(k) studies in the United States.

Asep Medical Holdings Inc. (ASEP) has signed a joint venture agreement with leading Chinese medical diagnostic company Sansure Biotech Inc. to form Hunan Sanway SepSMART Ltd. The new entity will focus on commercializing SepsetER, a rapid sepsis test, in China and surrounding areas, addressing a significant need in the market. The agreement represents a major milestone for Asep and supports its global manufacturing and distribution strategy.

Asep Medical Holdings Inc. (ASEP) is in the final stage of its approval process for the draft registration statement on Form F-1, filed with the SEC for its planned listing on the NASDAQ stock exchange. The company has also signed an agreement with Aegis Capital Corporation for the listing process. The size and price range for the proposed listing are yet to be determined, subject to market and SEC review process.

Asep Medical Holdings Inc. (Asep Inc.) (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) has completed the final milestone in its acquisition of SafeCoat Medical Inc. and entered into an exclusive worldwide license agreement with the University of British Columbia for a groundbreaking medical device coating technology. The technology aims to prevent device-related infections, which cost an additional $57,000 per patient and require device replacement. The estimated value of medical device coatings in 2022 was USD $5.8 billion and is estimated to grow to USD $9.7 billion by 2027, representing a compound annual growth rate (CAGR) of 10.9%. Asep Inc. will hold 88% of the issued and outstanding shares of SafeCoat, with UBC and the non-waiving inventors of the Technology owning the remaining 12%. The term of the Agreement will expire on the later of 20 years from the grant of the license and the expiry date of the last of the patents relating to the Technology.